Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
The Cochrane Database of Systematic Reviews|July 10, 2009
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient dataJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
Breast Care (Basel, Switzerland)|November 5, 2010
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)Matthias W Beckmann, Jens-Uwe Blohmer, Serban-Dan Costa, et al.
BMC Medicine|October 8, 2024
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancerPhilipp Zimmer, Tobias Esser, Diana Lueftner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2019
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)Ingrid A Mayer, Aleix Prat, Daniel Egle, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2023
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancerPaolo Nuciforo, John Townend, Martine J Piccart, et al.
Breast (Edinburgh, Scotland)|April 5, 2025
Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBCElena Laakmann, Marcus Schmidt, Kristina Lübbe, et al.
Cancers|October 21, 2020
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with PertuzumabLaura L Michel, Andreas D Hartkopf, Peter A Fasching, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT RegistryAndreas D Hartkopf, Christina B Walter, Hans-Christian Kolberg, et al.
BMC Cancer|October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtypePhilipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
Breast (Edinburgh, Scotland)|February 14, 2025
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancerChristina B Walter, Andreas D Hartkopf, Alexander Hein, et al.
Pageof 10